Jeppson Wealth Management LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,713 shares of the healthcare product maker’s stock after selling 120 shares during the period. Jeppson Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,551,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Future Financial Wealth Managment LLC acquired a new stake in Abbott Laboratories in the third quarter worth $31,000. Peterson Financial Group Inc. bought a new position in shares of Abbott Laboratories during the 3rd quarter worth about $32,000. Valued Wealth Advisors LLC grew its stake in shares of Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares during the period. Highline Wealth Partners LLC bought a new stake in Abbott Laboratories in the 3rd quarter valued at about $37,000. Finally, JDM Financial Group LLC raised its stake in Abbott Laboratories by 51.3% during the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock worth $41,000 after buying an additional 123 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.
Abbott Laboratories Trading Up 3.6 %
NYSE ABT opened at $129.51 on Tuesday. The business’s fifty day moving average is $115.26 and its 200-day moving average is $113.46. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock has a market capitalization of $224.63 billion, a price-to-earnings ratio of 16.93, a PEG ratio of 2.51 and a beta of 0.73. Abbott Laboratories has a one year low of $99.71 and a one year high of $129.76.
Abbott Laboratories Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 30.85%.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. Sanford C. Bernstein raised their price objective on Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Mizuho boosted their price target on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a research note on Thursday, October 17th. Barclays reaffirmed an “overweight” rating and issued a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research note on Monday. UBS Group boosted their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company raised their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.06.
View Our Latest Stock Analysis on ABT
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Recommended Stories
- Five stocks we like better than Abbott Laboratories
- How to Effectively Use the MarketBeat Ratings Screener
- What Does the Future Hold for Eli Lilly?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
- When to Sell a Stock for Profit or Loss
- 3 Consumer Stocks Call Option Traders Are Betting Big On
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.